Sanofi Reports Phase 3 subgroup analysis Data for Benralizumab in Urothelial carcinoma

Sanofi today announced Phase 3 subgroup analysis results for Benralizumab in patients with Urothelial carcinoma. The study demonstrated that Benralizumab demonstrates sustained long-term efficacy compared to standard of care or placebo. These results provide important insights into the treatment of Urothelial carcinoma and support the continued development of Benralizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Benralizumab was consistent with previous observations, with no new safety signals identified.